172 related articles for article (PubMed ID: 34234243)
1. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
Hahn L; Lim H; Dusyk T; Sabry W; Elemary M; Stakiw J; Danyluk P; Bosch M
Sci Rep; 2021 Jul; 11(1):14071. PubMed ID: 34234243
[TBL] [Abstract][Full Text] [Related]
2. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Wu R; Ma L
Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Hueso T; Gastinne T; Garciaz S; Tchernonog E; Delette C; Casasnovas RO; Durot E; Houot R; Tessoulin B; Tournilhac O; Malak S; Gyan E; Fornecker LM; Abraham J; Delapierre B; Peyrade F; Lemal R; Gressin R; Chantepie S; Borel C; Morello R; Bouabdallah K; Ibrahim A; Bouabdallah R; Le Gouill S; Damaj G
Bone Marrow Transplant; 2020 Jun; 55(6):1076-1084. PubMed ID: 31953532
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Costes-Tertrais D; Hueso T; Gastinne T; Thieblemont C; Oberic L; Bouabdallah K; Garciaz S; Tchernonog E; Dartigeas C; Ribrag V; Fogarty P; Casasnovas RO; Houot R; Delette C; Malak S; Fornecker LM; Gressin R; Damaj G; Le Gouill S
Bone Marrow Transplant; 2022 Apr; 57(4):627-632. PubMed ID: 35149851
[TBL] [Abstract][Full Text] [Related]
6. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
Plante MÉ; Feng X; Boudreault JS
Leuk Lymphoma; 2023; 64(7):1234-1242. PubMed ID: 37154396
[TBL] [Abstract][Full Text] [Related]
7. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation.
Frankiewicz A; Saduś-Wojciechowska M; Najda J; Czerw T; Mendrek W; Sobczyk-Kruszelnicka M; Soska K; Ociepa M; Hołowiecki J; Giebel S
Contemp Oncol (Pozn); 2018; 22(2):113-117. PubMed ID: 30150889
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
9. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
[TBL] [Abstract][Full Text] [Related]
11. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
Reid RM; Baran A; Friedberg JW; Phillips GL; Liesveld JL; Becker MW; Wedow L; Barr PM; Milner LA
Cancer Med; 2016 Nov; 5(11):3059-3067. PubMed ID: 27699999
[TBL] [Abstract][Full Text] [Related]
12. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
14. A low thrombospondin-1 serum concentration is related to increased bacteremia risk in lymphoma patients treated with BeEAM/BEAM conditioning regimen and autologous stem cell transplantation.
Kościelny K; Mikulski D; Nowicki M; Wyka K; Misiewicz M; Perdas E; Wierzbowska A; Fendler W
Transpl Infect Dis; 2024 Feb; 26(1):e14212. PubMed ID: 38112043
[TBL] [Abstract][Full Text] [Related]
15. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
16. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A
Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830
[TBL] [Abstract][Full Text] [Related]
17. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
[TBL] [Abstract][Full Text] [Related]
18. Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.
Tardy MP; Gastaud L; Ojeda-Uribe M; Boscagli A; Caruso S; Skaf R; Gutnecht J; Thyss A; Peyrade F
Exp Hematol Oncol; 2015; 4():18. PubMed ID: 26185733
[TBL] [Abstract][Full Text] [Related]
19. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]